drugset / Trial / NCT06067568

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

NCT06067568

Phase 1 Completed 50 enrolled AbbVie
RandomizedSequentialOpen-labelBasic science

Summary

The purpose of this study is to compare the bioavailability of two different formulations of lutikizumab, and to assess adverse events (AEs) and how lutikizumab moves through the body in healthy Chinese participants.

Timeline

Start
2023-09-28
Primary completion
2024-02-26
Completion
2024-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Lutikizumab Monoclonal antibody Subcutaneous

Indications

No indication recorded.